Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors (IVY)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02009449
Recruitment Status : Active, not recruiting
First Posted : December 12, 2013
Last Update Posted : September 5, 2021
ARMO BioSciences
Information provided by (Responsible Party):
Eli Lilly and Company